ClinicalTrials.gg
CompletedNCT04289285Updated Apr 11, 2022

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

A Phase 3 interventional study of IBI306 450mg SC Q4W and Placebo SC Q4W in Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
804
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
11th of 53
804 · median 207
Started
2020
with 2 others
Phase 3
25 of 59
4 open now
Registered
25th of 59
by date
Lead sponsor
4 of 59
Innovent Biologics (Suzhou) Co. Ltd.

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 11th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2020, is one of 25 in phase 3, and was the 25th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C) uptake. This study is being done to investigate the effects of IBI306 in Chinese people with non-familial hypercholesterolemia with very high or high cardiovascular risk. This study will see if IBI306 will reduce low density lipoprotein cholesterol (LDL-C) in Chinese people who are taking a certain type of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side effects

Read the detailed description

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of IBI306 in Chinese non-familial hypercholesterolemia Subjects with very high or high cardiovascular risk. A total of around 600 subjects who meet admission criteria will be randomized and receive one of the two dose levels of IBI306 or matching placebo: 450mg Q4W, or 600mg Q6W. The double blind period for both groups will be 48 weeks. The study will last 52 weeks

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 to ≤ 75 years of age
  2. Diagnosis of hypercholesterolemia
  3. LDL cholesterol ≥ 70 mg/dl (1.8mmol/L)
  4. Very high or high cardiovascular risk
  5. TG≤500 mg/dL(5.64 mmol/L)

Exclusion criteria

Exclusion criteria:

  1. Diagnosis of HoFH or HeFH
  2. Uncontrolled hypertension
  3. Uncontrolled hyperthyroidism or hypothyroidism
  4. Severe renal dysfunction
  5. Known sensitivity to any of the products to be administered during dosing
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
804 participants (actual)

Study arms

  • Experimental
    IBI306 450mg SC Q4W

    Drug: IBI306 450mg SC Q4W

  • Placebo comparator
    Placebo SC Q4W

    Drug: Placebo SC Q4W

  • Experimental
    IBI306 600mg SC Q6W

    Drug: IBI306 600mg SC Q6W

  • Placebo comparator
    Placebo SC Q6W

    Other: Placebo SC Q6W

Interventions

  • Subjects will receive IBI306 450mg every 4 weeks subcutaneously.

  • DrugPlacebo SC Q4W

    Subjects will receive placebo every 4 weeks subcutaneously.

  • Subjects will receive IBI306 600mg every 6 weeks subcutaneously.

  • OtherPlacebo SC Q6W

    Subjects will receive placebo every 6 weeks subcutaneously.

06

What researchers measure

Primary outcomes

  1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48

    Time frame: Week 48

Secondary outcomes

  1. The percent of subjects with LDL-C reduction no less than 50% from baseline

    Time frame: Week 48

  2. The percent of subjects with LDL-C<70mg/dL(1.8 mmol/L)

    Time frame: Week 48

  3. The percent change in Lp(a),ApoB, non-HDL-c, ApoB/ApoA1 from baseline

    Time frame: Week 48

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Feb 2022, 21 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Feb 28, 2020
StartActual
Apr 29, 2020
Primary completionActual
Feb 9, 2022
CompletionActual
Feb 9, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04289285
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Apr 29, 2020
Primary completion
Feb 9, 2022
Completion
Feb 9, 2022
Last update
Apr 11, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion